Home > Compound List > Product Information
Doxazosin_Molecular_structure_CAS_74191-85-8)
Click picture or here to close

Doxazosin

Catalog No. DB00590 Name DrugBank
CAS Number 74191-85-8 Website http://www.ualberta.ca/
M. F. C23H25N5O5 Telephone (780) 492-3111
M. W. 451.4751 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 472

SYNONYMS

IUPAC name
2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
IUPAC Traditional name
2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
Brand Name
Alfadil
Diblocin
Cardura XL
Cardura-2
Cardenalin
Cardular
Cardura
Cardura-1
Cardura-4
Carduran
Normothen
Supressin
Synonyms
Doxazosin mesilate
Doxazosin mesylate

DATABASE IDS

PubChem SID 46506825
CAS Number 74191-85-8
PubChem CID 3157

PROPERTIES

Hydrophobicity(logP) 2.1
Solubility 24 mg/L

DETAILS

Description (English)
Item Information
Drug Groups approved
Description Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors. It may be used to mild to moderate hypertension and in the management of symptomatic benign prostatic hyperplasia (BPH). α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland.
Indication For treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH.
Pharmacology Doxazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Doxazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Doxazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Doxazosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Doxazosin results from a decrease in systemic vascular resistance and the parent compound Doxazosin is primarily responsible for the antihypertensive activity.
Toxicity Symptoms of overdose include hypotension. Oral LD50 is greater than 1000 mg/kg in mice and rats.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic.
Absorption 65%
Half Life 22 hours
Protein Binding 98%
Elimination On average only 4.8% of the dose was excreted as unchanged drug in the feces and only a trace of the total radioactivity in the urine was attributed to unchanged drug.
References
Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

REFERENCES

  • Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. Pubmed